After receiving the ethical approval in Tanzania, NeuroSolve obtained the ethical clearance in Zambia too. The ethical clearance certificate will allow to conduct medical research on Neurocysticercosis also in Zambia.

NeuroSolve is a four-year project funded by the European Commission and EDCTP3, started on May 1, 2023. The African Institutions involved are: University of Dar es Salaam (Tanzania), Sokoine University of Agriculture (Tanzania), University of Zambia (Zambia); the European Institutions are: Universiteit Ghent (Belgium) and R-Evolution Worldwide Srl – Impresa Sociale (Italy), that is also the project Coordinator. NeuroSolve is committed to fight taeniasis/Neurocysticercosis (NCC) disease in Sub-Saharan Africa.

Potrebbe essere un'immagine raffigurante testo

Leave a Reply

Your email address will not be published. Required fields are marked *

Explore More

Second International Conference on Public Health in Africa

  The Second International Conference on Public Health in Africa (CPHIA) was held in Kigali on 13th-15th December 2022. In CPHIA 2022 conference were addressed discussion on need to ensure global health

NeuroSolve Project Kick-off Meeting in Lusaka, Zambia

The NeuroSolve consortium held its Project Kick-off Meeting on the 4th December 2023 in Lusaka (Zambia). NeuroSolve is a four-year project funded by EDCTP3, lead by an African-European research consortium

OPTIMAL-RSV AFRICA PROPOSAL SUBMITTED TO EDCTP3 TO IMPROVING NEWBORN PROTECTION AGAINTS RESPIRATORY INFECTION IN AFRICA

Respiratory infections remain one of the main causes of illness and death among newborns in sub-Saharan Africa. Respiratory Syncytial Virus (RSV) is a major contributor to severe disease in the